STXS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Stereotaxis Inc (STXS) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock shows no clear bullish technical signals, and its financial performance has been weak with declining revenue and EPS. While there is a positive analyst rating and a favorable price target, the lack of recent positive news, weak trading trends, and bearish technical indicators suggest waiting for a better entry point.
The technical indicators for STXS are bearish. The MACD is below zero and negatively contracting, the RSI is neutral at 46.859, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 2.056, with resistance at 2.13 and support at 1.983. Historical trends suggest a high probability of short-term declines.
Analyst coverage initiated with an Outperform rating and a $4 price target, citing the company's unique position in MedTech and potential tailwinds for system adoption.
Weak financial performance in Q3 2025 with a revenue decline of -18.83% YoY and a drop in EPS by -12.50% YoY. No recent news or significant trading trends from insiders or hedge funds. Technical indicators and stock trend analysis suggest potential short-term declines.
In Q3 2025, revenue dropped by -18.83% YoY to $7.46M. Net income improved slightly by 4.10% YoY to -$6.79M, but EPS declined by -12.50% YoY to -0.07. Gross margin improved significantly by 23.27% YoY to 54.94%. Overall, the financial performance shows mixed signals with declining top-line growth but some improvement in margins.
Citizens initiated coverage with an Outperform rating and a $4 price target, citing the company's unique position in the MedTech space and potential for growth through 2026.
